BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park, Room 561

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Drug Discovery





 Company News
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Announces Accepted Abstracts At The 2014 Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 7/24/2014 10:03:57 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Phase 3 Study Of I.V. And Oral Delafloxacin Has Begun Enrolling Patients With Acute Bacterial Skin And Skin Structure Infections 5/5/2014 12:27:16 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) To Present At Needham & Company's Annual Healthcare Conference 4/3/2014 1:56:25 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Scores $70 Million To Fund Lead Drug Trial 2/10/2014 7:14:58 AM
Rib-X Pharmaceuticals, Inc. Presents Data Demonstrating Potent In Vitro Activity of Delafloxacin Against Drug-Resistant Gonorrhea 7/16/2013 10:13:00 AM
Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections 5/14/2013 9:58:00 AM
Rib-X Pharmaceuticals, Inc. Appoints John E. Sununu to the Board of Directors 5/13/2013 7:18:26 AM
Rib-X Pharmaceuticals, Inc. Announces New Executive Leadership and Board of Directors Appointments 4/3/2013 10:50:41 AM
Rib-X Pharmaceuticals, Inc. Appoints New Chair of Board of Directors 1/4/2013 6:27:41 AM
Rib-X Pharmaceuticals, Inc.' RX-04 Program Will be Featured at Windhover Information Inc.'s Therapeutic Area Partnerships Meeting as a "Top 10 Infectious Diseases Project to Watch" 11/29/2012 9:51:54 AM
12345678